Project management software maker Monday.com (NASDAQ:MNDY) announced better-than-expected revenue in Q1 CY2025, with sales up 30.1% year on year to $282.3 million. The company expects next quarter’s revenue to be around $293 million, close to analysts’ estimates. Its non-GAAP profit of $1.10 per share was 56.4% above analysts’ consensus estimates.
Beauty supply retailer Sally Beauty (NYSE:SBH) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 2.8% year on year to $883.1 million. On the other hand, the company expects next quarter’s revenue to be around $942.3 million, close to analysts’ estimates. Its non-GAAP profit of $0.42 per share was 6.6% above analysts’ consensus estimates.
The company has shown its revolutionary technology can deliver life-changing therapies. Now, it's about whether CRISPR Therapeutics can replicate the success across its promising pipeline.
Fresh produce company Dole (NYSE:DOLE) announced better-than-expected revenue in Q1 CY2025, but sales fell by 1% year on year to $2.10 billion. Its non-GAAP profit of $0.35 per share was 10.7% below analysts’ consensus estimates.
Swimming pool distributor Pool (NASDAQ:POOL) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 4.4% year on year to $1.07 billion. Its GAAP profit of $1.42 per share was 4.1% below analysts’ consensus estimates.
Bitcoin (CRYPTO: BTC) has seen a stratospheric rise since its inception in 2009. Those who identified its potential and invested when it was still in its infancy have witnessed returns that very few assets can compete with.
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 5.6% year on year to $11.2 billion. The company’s full-year revenue guidance of $46.3 billion at the midpoint came in 1.2% above analysts’ estimates. Its non-GAAP profit of $1.80 per share was 19.8% above analysts’ consensus estimates.
